Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug?

摘要: In the past decade, clinical practice in rheumatology has been transformed by advent of ‘biologicals’. The use these new drugs significantly improved outcome patients with rheumatoid arthritis especially for those refractory to (patient-tailored) conventional disease-modifying antirheumatic drug (DMARD) therapy. question is, is it now time a gap-bridging, large step forward treatment an even more commonly seen rheumatic disease, osteoarthritis? Has era osteoarthritis (DMOAD) begun? Is ‘OA RA’ (quote from Professor P Conaghan, 2012 annual meeting British Society Rheumatology (BSR)), or this still wishful thinking? It no longer needs proclamation worldwide numbers who suffer non-attendance and decreased productivity at work unemployment, costs medical paramedical care, medication use, surgical treatments joint replacement end, recognise that huge socioeconomic problem.1 Osteoarthritis most common disabling disease worldwide. Moreover, its incidence prevalence are increasing because ageing, higher life expectancy, lifestyle changes, leading growing population osteoarthritis.2 Osteoarthritis clinically characterised primarily pain consequently functional limitations. Cartilage degradation considered pivotal pathology. This might be surprising, since cartilage not innervated, so osteoarthritic must arise other tissues involved. Changes periarticular bone, synovial tissue soft structures such as ligaments muscles inextricably related process. Obviously, all structural changes part cascade eventually leads overt osteoarthritis, they need unison when symptoms. sequence relative importance each processes may differ between individuals, joints, …